Literature DB >> 6593111

HLA antigens, autoantibodies and clinical subsets in scleroderma.

C M Black, K I Welsh, P J Maddison, M I Jayson, R M Bernstein.   

Abstract

The HLA antigens were determined in 54 Caucasoid patients with scleroderma (ARA criteria). All were assessed for extent of skin and organ involvement, anticentromere (ACA), and scleroderma 70 (Scl 70) antibodies. The antigens DR1, DR3 and DR5 were raised in the patient group, and DR2 was lowered. Of these only the increase in DR5 was significant (chi 2 = 5.2; p = 0.02). The increased frequency of DR3 was attributable to a rise in the A1, B8, DR3 haplotype (chi 2 = 3.9; p = 0.05). Patients with non-diffuse disease showed a significant increase in the DR1 and DR5 antigens (chi 2 = 3.7, p = 0.05; chi 2 = 8.0, p = 0.01). No association was found between the HLA antigens and specific organ involvement. Anticentromere antibodies were present in 15 of the HLA-DR typed patients. Thirteen of these 15 patients were either DR1 or DR5. No relationship was found between the frequencies of HLA antigens and anti-Scl 70 antibodies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6593111     DOI: 10.1093/rheumatology/23.4.267

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  14 in total

Review 1.  Epidemiology of scleroderma.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 2.  Major histocompatibility complex class II genes and systemic sclerosis.

Authors:  D Briggs; K I Welsh
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

3.  Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion.

Authors:  M Jarzabek-Chorzelska; M Blaszczyk; Z Kolacinska-Strasz; T Chorzelski; S Jabłońska; G G Maul
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

4.  Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis.

Authors:  P J Maddison; R P Skinner; R S Pereira; C M Black; B M Ansell; M I Jayson; N R Rowell; K I Welsh
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

5.  Genes associated with rheumatoid arthritis and mild inflammatory arthritis. I. Major histocompatibility complex class I, II, and III allotypes.

Authors:  A H Puttick; D C Briggs; K I Welsh; R Vaughan; E A Williamson; M Boyce; R K Jacoby; V E Jones
Journal:  Ann Rheum Dis       Date:  1990-04       Impact factor: 19.103

6.  Family studies in scleroderma (systemic sclerosis) demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes.

Authors:  G Rittner; G Schwanitz; M P Baur; C M Black; K I Welsh; P Kühnl; C Rittner
Journal:  Hum Genet       Date:  1988-12       Impact factor: 4.132

7.  Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study.

Authors:  N J McHugh; J Whyte; C Artlett; D C Briggs; C O Stephens; N J Olsen; N G Gusseva; P J Maddison; C M Black; K Welsh
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

8.  Antinuclear antibodies in patients with scleroderma (systemic sclerosis) and in their blood relatives and spouses.

Authors:  A J Barnett; L J McNeilage
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

9.  The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).

Authors:  M Kuwana; J Kaburaki; Y Okano; H Inoko; K Tsuji
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

Review 10.  Clinical aspects of systemic sclerosis (scleroderma).

Authors:  R M Silver
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.